ArticleOpen veterinary journal2026
Magnesium oxide nanoparticles: A novel shield against CCl₄-induced hepatic damage via caspase-3 and TNF-α in rats.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbon tetrachloride (CCl₄) is a widely used hepatotoxin that induces liver injury through apoptosis and inflammation. Magnesium oxide (MgO) nanoparticles have shown potential hepatoprotective effects, which may depend on synthesis conditions such as pH. Aim: This study aimed to investigate the hepatoprotective effects of biosynthesized MgO nanoparticles from Methods: MgO nanoparticles were biosynthesized at pH 5 and pH 9 and characterized for crystalline structure (X-ray diffraction), elemental composition (energy-dispersive spectroscopy), and thermal stability (thermogravimetry). Male Wistar rats were divided into six groups: control negative, control positive (CCl₄), MgO pH 5, MgO pH 5 + CCl₄, MgO pH 9, and MgO pH 9 + CCl₄. Liver sections were immunohistochemically evaluated for caspase-3 and Tumor necrosis factor-alpha (TNF-α) expression using immunohistochemistry. Staining was assessed semiquantitatively based on intensity and percentage of positive cells, and a final immunoreactivity score was calculated as Intensity × % positive cells. Results: Characterization confirmed the successful synthesis and structural features of MgO nanoparticles. CCl₄ exposure increased caspase-3 and TNF-α immunoexpression, with higher scores observed in the CCl₄ group (caspase-3 = 12; TNF-α = 10) compared with the control group (score = 0 for both markers). MgO nanoparticles reduced caspase-3 and TNF-α expression in a pH-dependent manner. The pH 5 formulation showed moderate reduction (caspase-3 = 6; TNF-α = 6), whereas the pH 9 formulation showed greater reduction (caspase-3 = 4; TNF-α = 2), indicating a stronger protective trend. Conclusion: MgO nanoparticles mitigate apoptosis and inflammation in CCl₄-induced liver injury, with higher efficacy observed for nanoparticles synthesized at pH 9, highlighting the importance of synthesis conditions for optimizing hepatoprotective activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.